 Patents Granted in the United States, China, South Korea, Japan, Israel and New Zealand for Dermal Injector and Tendon Regeneration Technologies VANCOUVER, BC ACCESSWIRE May 5, 2021 RepliCel Life Sciences Inc. OTCQB:REPCFTSXV:RPFRA:P6P2 RepliCel or the Company, a company developing next-generation regenerative medicine technologies in aesthetics and orthopedics, is pleased to announce the granting andor allowance of seven patent applications since December 2020. The two patent families involved are REPL 403 related in the RepliCel dermal injector and REPL 407 related to compositions and methods for treating and repairing tendons. 